AtriCure Q2 2024 revenue $116.3M (+15.2% YoY); net loss $0.17/share

AtriCure, Inc.

2024-Q2 EPS reported -$0.45 revenue$225,120,000

Worldwide revenue $116.3M, up 15.2% YoY (15.4% constant currency); U.S. $95.5M (+12.5%), international $20.7M (+29.4%).
Gross margin 74.7%, down 168 bps YoY due to mix and product costs; operating loss $7.2M vs $4.1M loss.
Net loss per share $0.17 vs $0.11; adjusted EBITDA $7.8M, down $0.2M vs Q2 2023.
Generated positive cash flow of $8.1M during the quarter.
CEO cited strong growth from pain management and AtriClip franchises; advancing LeAAPS trial and new product launches.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.